The global cell therapy raw materials market size was estimated to be USD 4.32 billion in 2023 and is expected to reach at USD 48.04 billion by 2034 with a CAGR of 24.48% during the forecast period 2024-2034. The surge in chronic diseases like cancer, diabetes, & autoimmune disorders, heightened research & development efforts, major industry players are making substantial investments, an escalating need for regenerative & personalized medicines, leveraging rapid technological advancements, rising merger & acquisition activity among leading companies, emphasizing the strategic importance of expanding product & service portfolios, and increase in the introduction of new cell therapy human raw material products are some of the key factors boosting the market growth.
Increase in introduction of new cell therapy human raw material products is predicted to boost the market growth during the forecast period. The expanding realm of cell therapy is driving a heightened need for specialized human raw materials crucial to this groundbreaking medical approach. Consequently, numerous companies are broadening their array of products centered around cell therapy. For instance, in July 2023, PromoCell GmbH recently launched a novel product, the PromoExQ MSC Growth Medium XF, designed for the manufacturing of cell therapy.
By product, cell culture media was the highest revenue-grossing segment in the global cell therapy raw materials market in 2023 owing to the many companies are heavily investing in advancing cell culture media to improve the efficiency of the cell therapy process, and increase in the introduction of novel cell culture mediums. For instance, in May 2023, Lonza has unveiled the TheraPEAK T-VIVO Cell Culture Medium with the aim of accelerating the progress of cell therapy development. Additionally, antibodies is predicted to grow at the fastest CAGR during the forecast period owing to the increasing importance of media and antibodies in cell-based therapies for targeted treatments & immune modulation, growing incidence of cancer, infectious diseases, & autoimmune disorders, coupled with a surge in advancements in biotechnology and recombinant DNA technology.
By end-user, biopharmaceutical & pharmaceutical companies was the highest revenue-grossing segment in the global cell therapy raw materials market in 2023 owing to the increasing need for cell-based therapies, supported by sophisticated healthcare infrastructure, rising investments in research & development, upsurge in the establishment of advanced manufacturing facilities, and numerous research institutes and biopharmaceutical and pharmaceutical companies are actively engaged in the development of cell therapies. For instance, in August 2023, Cellectis is currently conducting trials on three chimeric antigen receptor (CAR) T-cell treatments, namely UCART22, UCART123, and UCART20x22. These clinical trials are named NATHALI-01, BALLI-01, and AMELI-01. Additionally, CROs & CMOs is predicted to grow at the fastest CAGR during the forecast period. Contract Research Organizations (CROs) provide essential services in both preclinical and clinical research, playing a crucial role in advancing cell therapy development by offering expertise in trial design, patient recruitment, and regulatory compliance. Similarly, Contract Manufacturing Organizations (CMOs) offer more efficient and economical manufacturing solutions to biopharmaceutical companies that lack the necessary expertise. As a result of delivering highly specialized services, CROs and CMOs have become pivotal players in the end-use sector.
North America region is anticipated for the highest revenue share during the forecast period owing to the favorable government regulations, a rising appetite for groundbreaking therapeutics, and concerted endeavors by major market players to progress cell-based therapy products for treating various chronic disorders, numerous prominent companies are actively engaged in the production & commercialization of cell-based products, and increase in the introduction of novel offerings. For instance, in November 2023, ACROBiosystems has unveiled the introduction of GMP-grade DLL4, which is a recombinant, soluble variant of Delta-like Ligand 4 (DLL4). This product, essential for stem cell manufacturing, stands out in the market as one of the limited offerings produced under GMP conditions. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing emphasis on biotechnology, surge in prevalence of chronic & degenerative disorders, escalating demand for cutting-edge cell therapies, increase in research and development initiatives, and surge in launch of new products by key industry players. For instance, in June 2023, FUJIFILM Cellular Dynamics, a prominent global developer and manufacturer of human induced pluripotent stem cells (iPSC), has officially launched its human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit worldwide. This kit is designed for scientists involved in neuroscience research and drug discovery specifically for neuroactive drugs.
Increase in introduction of new cell therapy human raw material products is predicted to boost the market growth during the forecast period. The expanding realm of cell therapy is driving a heightened need for specialized human raw materials crucial to this groundbreaking medical approach. Consequently, numerous companies are broadening their array of products centered around cell therapy. For instance, in July 2023, PromoCell GmbH recently launched a novel product, the PromoExQ MSC Growth Medium XF, designed for the manufacturing of cell therapy.
By product, cell culture media was the highest revenue-grossing segment in the global cell therapy raw materials market in 2023 owing to the many companies are heavily investing in advancing cell culture media to improve the efficiency of the cell therapy process, and increase in the introduction of novel cell culture mediums. For instance, in May 2023, Lonza has unveiled the TheraPEAK T-VIVO Cell Culture Medium with the aim of accelerating the progress of cell therapy development. Additionally, antibodies is predicted to grow at the fastest CAGR during the forecast period owing to the increasing importance of media and antibodies in cell-based therapies for targeted treatments & immune modulation, growing incidence of cancer, infectious diseases, & autoimmune disorders, coupled with a surge in advancements in biotechnology and recombinant DNA technology.
By end-user, biopharmaceutical & pharmaceutical companies was the highest revenue-grossing segment in the global cell therapy raw materials market in 2023 owing to the increasing need for cell-based therapies, supported by sophisticated healthcare infrastructure, rising investments in research & development, upsurge in the establishment of advanced manufacturing facilities, and numerous research institutes and biopharmaceutical and pharmaceutical companies are actively engaged in the development of cell therapies. For instance, in August 2023, Cellectis is currently conducting trials on three chimeric antigen receptor (CAR) T-cell treatments, namely UCART22, UCART123, and UCART20x22. These clinical trials are named NATHALI-01, BALLI-01, and AMELI-01. Additionally, CROs & CMOs is predicted to grow at the fastest CAGR during the forecast period. Contract Research Organizations (CROs) provide essential services in both preclinical and clinical research, playing a crucial role in advancing cell therapy development by offering expertise in trial design, patient recruitment, and regulatory compliance. Similarly, Contract Manufacturing Organizations (CMOs) offer more efficient and economical manufacturing solutions to biopharmaceutical companies that lack the necessary expertise. As a result of delivering highly specialized services, CROs and CMOs have become pivotal players in the end-use sector.
North America region is anticipated for the highest revenue share during the forecast period owing to the favorable government regulations, a rising appetite for groundbreaking therapeutics, and concerted endeavors by major market players to progress cell-based therapy products for treating various chronic disorders, numerous prominent companies are actively engaged in the production & commercialization of cell-based products, and increase in the introduction of novel offerings. For instance, in November 2023, ACROBiosystems has unveiled the introduction of GMP-grade DLL4, which is a recombinant, soluble variant of Delta-like Ligand 4 (DLL4). This product, essential for stem cell manufacturing, stands out in the market as one of the limited offerings produced under GMP conditions. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing emphasis on biotechnology, surge in prevalence of chronic & degenerative disorders, escalating demand for cutting-edge cell therapies, increase in research and development initiatives, and surge in launch of new products by key industry players. For instance, in June 2023, FUJIFILM Cellular Dynamics, a prominent global developer and manufacturer of human induced pluripotent stem cells (iPSC), has officially launched its human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit worldwide. This kit is designed for scientists involved in neuroscience research and drug discovery specifically for neuroactive drugs.
Segmentation: Cell Therapy Raw Materials Market Report 2023 - 2034
Cell Therapy Raw Materials Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Cell Culture Supplements
- Proteins
- Nucleotides
- Growth Factors
- Other Supplements
- Cell Culture Sera
- Reagents & Buffers
- Cell Culture Media
- Antibodies
- Other Raw Materials
Cell Therapy Raw Materials Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- CROs & CMOs
- Academic & Research Institutions
- Biopharmaceutical & Pharmaceutical Companies
Cell Therapy Raw Materials Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cell Therapy Raw Materials Market: Product Estimates & Trend Analysis
8. Cell Therapy Raw Materials Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Cell Therapy Raw Materials Market
11. Europe Global Cell Therapy Raw Materials Market
12. Asia Pacific Global Cell Therapy Raw Materials Market
13. Latin America Global Cell Therapy Raw Materials Market
14. MEA Global Cell Therapy Raw Materials Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- ACROBiosystems
- Merck KGaA
- PromoCell GmbH
- Charles River Laboratories
- Actylis.
- Thermo Fisher Scientific Inc.
- Danaher
- STEMCELL Technologies.
- Sartorius Stedim Biotech
- Grifols S.A.
- RoosterBio Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.32 Billion |
| Forecasted Market Value ( USD | $ 48.04 Billion |
| Compound Annual Growth Rate | 24.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
